ERBB2 and breast carcinoma: Many reports have shown that HER2 and TOP2A co-amplification predicted a good response to TOP2A inhibitor chemotherapy in breast carcinoma, and that a combined therapy with HER2 inhibitors and TOP2A inhibitors would be a good choice for the treatment of these cancer patients.